A Chinese biotech company is leaning on artificial intelligence to speed up chromosome testing and lift profits, betting that the country’s shrinking fertility rate will keep demand for assisted reproduction growing. Hangzhou Diagens Biotechnology plans to use the technology to strengthen its business after a recent Hong Kong listing.
What Happened
Hangzhou Diagens Biotechnology is developing AI-powered chromosome testing as part of its push into fertility-related diagnostics. The company says the approach will help it fast-track in vitro fertilization, or IVF, by making testing more efficient and supporting doctors and patients who are turning to assisted reproduction.
Founder and executive director Song Ning said demand is increasing as more young people in China delay marriage and parenthood, leaving some couples needing medical help to conceive. “In China, many young people do not want to marry or have children, and by the time they decide to start a family, they need medical help to do so,” Song said.
Song also said the company is seeing more couples each year who struggle to have children, reflecting a broader shift in China’s fertility landscape. The company is banking on that trend to support growth after listing in Hong Kong.
Background
China has been grappling with a sustained decline in births for years, driven by later marriages, higher living costs, and changing social attitudes toward family life. That demographic pressure has pushed policymakers and businesses to look for ways to support fertility treatment and reproductive health services.
Chromosome testing is an important part of assisted reproduction because it can help identify genetic or chromosomal abnormalities that may affect embryo development or pregnancy outcomes. By introducing artificial intelligence into that process, biotech firms hope to improve speed, consistency, and scalability in fertility clinics.
Hong Kong has also become an important fundraising venue for mainland Chinese companies seeking capital from international investors, including firms in health care and biotechnology.
Why It Matters
The move highlights how China’s demographic slowdown is creating new commercial opportunities in fertility medicine and diagnostic technology. If AI-assisted chromosome testing becomes more widely adopted, it could help make IVF services more efficient and potentially easier to expand.
For readers in Panama and Latin America, the story is a reminder that fertility technology is advancing quickly in major Asian markets, where demographic decline is prompting fresh investment in reproductive health. While the company’s immediate focus is China, similar pressures around birth rates, health care access, and assisted reproduction are increasingly shaping policy and business decisions around the world.